BCN Biosciences is interested in collaborating with companies who have artificial intelligence capabilities for target discovery. BCN Biosciences has built expertise in the pathways leading to apoptosis in cancer cells through phenotypic screening methods. Computational methods of target ID are a new way of reducing time to target discovery and either optimizing lead candidates or validating targets. Normally targets are discovered and drugs are designed towards those targets. The benefit of this historic approach is knowing the target and discovering a new drug. The drawback is many companies rush to develop their own assets in this area. BCN applies phenotypic screening which gives a high propensity to discover new pathways or highly unusual targets. This is the benefit. The drawback for this approach is the time to discover the actual target. We are now in the era of artificial intelligence which stands to make this latter platform very competitive.
If you are an AI company who feels they have strengths in this area, pleas reach out to us at our contact page.
If you are an AI company who feels they have strengths in this area, pleas reach out to us at our contact page.